Circulating microRNAs in cancer: Origin, function and application

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Ma, Ruimin ^a   Jiang, Tao ^a   Kang, Xixiong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Circulating; Diagnosis; MicroRNA

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; INTERLEUKIN 10; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNTRANSLATED RNA; UVOMORULIN;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHEMOSENSITIVITY; CYTOKINE PRODUCTION; DRUG EFFICACY; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MACROPHAGE; MELANOMA; NON INVASIVE PROCEDURE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR CELL;

HUMANS; MICRORNAS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862236784     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-38     Document Type: Review

References (101)

1. microRNA and cancer. Li M, Li J, Ding X, He M, Cheng SY, AAPS J 2010 12 309 317
2. Most mammalian mRNAs are conserved targets of microRNAs. Friedman RC, Farh KK, Burge CB, Bartel DP, Genome Res 2009 19 92 105
3. Posttranscriptional regulation of microRNA biogenesis in animals. Siomi H, Siomi MC, Mol Cell 2010 38 323 332
4. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Kosaka N, Iguchi H, Ochiya T, Cancer Sci 2010 101 2087 2092
5. Let-7 expression defines two differentiation stages of cancer. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME, Proc Natl Acad Sci U S A 2007 104 11400 11405
6. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, et al. Oncogene 2007 26 7590 7595
7. Implication of microRNAs in drug resistance for designing novel cancer therapy. Sarkar FH, Li Y, Wang Z, Kong D, Ali S, Drug Resist Updat 2010 13 57 66
8. Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein. Huber K, Kirchheimer JC, Ermler D, Bell C, Binder BR, Cancer Res 1992 52 1717 1720
9. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Deftos LJ, Endocr Rev 1991 12 181 187
10. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F, BJU Int 1999 84 706 713
11. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC, Zurawski VR, Obstet Gynecol 1992 80 14 18
12. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Zagars GK, von Eschenbach AC, Cancer 1993 72 538 548
13. Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer. Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, Friese K, Jeschke U, BMC Cancer 2012 12 2
14. Two patients with extremely elevated tumor markers: where is the malignancy? van der Veek PP, de Vos Tot Nederveen Cappel WH, Langers AM, van Hoek B, Gastroenterol Res Pract 2011 2011 123743
15. Prostate-specific antigen. Stenman UH, Leinonen J, Zhang WM, Finne P, Semin Cancer Biol 1999 9 83 93
16. Detection and characterization of placental microRNAs in maternal plasma. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM, Clin Chem 2008 54 482 490
17. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. Br J Haematol 2008 141 672 675
18. Extracellular microRNA: a new source of biomarkers. Etheridge A, Lee I, Hood L, Galas D, Wang K, Mutat Res 2011 717 85 90
19. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X, Int J Cancer 2010 127 118 126
20. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT, Clin Cancer Res 2009 15 5473 5477
21. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B, Circ Cardiovasc Genet 2010 3 499 506
22. Detection of cancer with serum miRNAs on an oligonucleotide microarray. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B, PLoS One 2009 4 6229
23. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE, Gynecol Oncol 2009 112 55 59
24. Real-time quantification of microRNAs by stem-loop RT-PCR. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. Nucleic Acids Res 2005 33 179
25. Next-generation sequencing transforms todays biology. Schuster SC, Nat Methods 2008 5 16 18
26. MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep Sequencing. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Li Z, et al. PLoS One 2011 6 18286
27. MicroRNA profiles of prostate carcinoma detected by multi-platform miRNA screening. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, et al. Int J Cancer 2012 130 611 621
28. Discovery of novel human breast cancer microRNAs from deep sequencing data by analysis of pri-microRNA secondary structures. Ryu S, Joshi N, McDonnell K, Woo J, Choi H, Gao D, McCombie WR, Mittal V, PLoS One 2011 6 16403
29. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. Chen Y, Gelfond JA, McManus LM, Shireman PK, BMC Genomics 2009 10 407
30. Circulating microRNAs as stable blood-based markers for cancer detection. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, OBriant KC, Allen A, et al. Proc Natl Acad Sci U S A 2008 105 10513 10518
31. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Cell Res 2008 18 997 1006
32. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA, Cancer Lett 2009 283 168 175
33. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO, Nat Cell Biol 2007 9 654 659
34. Secretory mechanisms and intercellular transfer of microRNAs in living cells. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T, J Biol Chem 2010 285 17442 17452
35. Selective release of microRNA species from normal and malignant mammary epithelial cells. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM, PLoS One 2010 5 13515
36. Versatile applications of microRNA in anti-cancer drug discovery: from therapeutics to biomarkers. Iguchi H, Kosaka N, Ochiya T, Curr Drug Discov Technol 2010 7 95 105
37. Export of microRNAs and microRNA-protective protein by mammalian cells. Wang K, Zhang S, Weber J, Baxter D, Galas DJ, Nucleic Acids Res 2010 38 7248 7259
38. Characterization of extracellular circulating microRNA. Turchinovich A, Weiz L, Langheinz A, Burwinkel B, Nucleic Acids Res 2011 39 7223 7233
39. MicroRNA expression profiles in umbilical cord blood cell lineages. Merkerova M, Vasikova A, Belickova M, Bruchova H, Stem Cells Dev 2010 19 17 26
40. Immunotherapeutic approaches for glioma. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M, Crit Rev Immunol 2009 29 1 42
41. MicroRNAs in immune regulation-opportunities for cancer immunotherapy. Okada H, Kohanbash G, Lotze MT, Int J Biochem Cell Biol 2010 42 1256 1261
42. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, OLeary JJ, Ruan Q, Johnson DS, Chen Y, ONeill LA, Nat Immunol 2010 11 141 147
43. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K, Mol Cell 2010 39 493 506
44. MicroRNA-155 is induced during the macrophage inflammatory response. OConnell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D, Proc Natl Acad Sci U S A 2007 104 1604 1609
45. Circulating miRNAs are correlated with tumor progression in prostate cancer. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H, Int J Cancer 2011 128 608 616
46. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ, Gut 2009 58 1375 1381
47. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, Muller SC, et al. PLoS One 2011 6 25787
48. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K, Urol Oncol 2010 28 4 13
49. MicroRNA-directed cleavage of HOXB8 mRNA. Yekta S, Shih IH, Bartel DP, Science 2004 304 594 596
50. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G, Nature 2000 403 901 906
51. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Olsen PH, Ambros V, Dev Biol 1999 216 671 680
52. MicroRNA-373 induces expression of genes with complementary promoter sequences. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R, Proc Natl Acad Sci U S A 2008 105 1608 1613
53. Small dsRNAs induce transcriptional activation in human cells. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R, Proc Natl Acad Sci U S A 2006 103 17337 17342
54. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Olive V, Jiang I, He L, Int J Biochem Cell Biol 2010 42 1348 1354
55. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Peter ME, Cell Cycle 2009 8 843 852
56. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Ma L, Teruya-Feldstein J, Weinberg RA, Nature 2007 449 682 688
57. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al. Nat Cell Biol 2008 10 202 210
58. MicroRNA-125b is a novel negative regulator of p53. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B, Genes Dev 2009 23 862 876
59. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY, Cell 2010 142 914 929
60. miR-155: on the crosstalk between inflammation and cancer. Tili E, Croce CM, Michaille JJ, Int Rev Immunol 2009 28 264 284
61. Tolerance versus immune response - microRNAs as important elements in the regulation of the HLA-G gene expression. Veit TD, Chies JA, Transpl Immunol 2009 20 229 231
62. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L, Cancer Res 2006 66 9290 9298
63. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, Pineiro A, Larrad L, Alava MA, Naval J, et al. J Immunol 2001 167 6736 6744
64. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD, J Immunol 2005 174 6440 6448
65. Tumor-released microvesicles as vehicles of immunosuppression. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L, Cancer Res 2007 67 2912 2915
66. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, et al. Nat Genet 2006 38 1060 1065
67. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, Hofmann WK, Zeiher AM, Dimmeler S, Blood 2010 115 4944 4950
68. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, Tetta C, Bussolati B, Camussi G, Cancer Res 2011 71 5346 5356
69. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S, Circ Res 2007 101 59 68
70. MicroRNAs as novel regulators of angiogenesis. Suarez Y, Sessa WC, Circ Res 2009 104 442 454
71. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Urbich C, Kuehbacher A, Dimmeler S, Cardiovasc Res 2008 79 581 588
72. The Sir2 family of protein deacetylases. Blander G, Guarente L, Annu Rev Biochem 2004 73 417 435
73. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Haigis MC, Guarente LP, Genes Dev 2006 20 2913 2921
74. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Zhao T, Li J, Chen AF, Am J Physiol Endocrinol Metab 2010 299 110 116
75. Chemokines direct endothelial progenitors into tumor neovessels. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R, Proc Natl Acad Sci U S A 2005 102 18111 18116
76. Next-generation sequencing of microRNAs for breast cancer detection. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q, J Biomed Biotechnol 2011 2011 597145
77. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS, Clin Chem 2011 57 84 91
78. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ, J Thorac Oncol 2011 6 482 488
79. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ, Chin J Cancer 2011 30 407 414
80. Circulating microRNAs as biomarkers for hepatocellular carcinoma. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M, J Clin Gastroenterol 2011 45 355 360
81. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, et al. Mol Carcinog 2011 50 136 142
82. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M, et al. J Dermatol Sci 2011 61 187 193
83. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, et al. Eur J Cancer 2011 47 784 791
84. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX, Int J Clin Exp Pathol 2011 4 575 586
85. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al. PLoS One 2012 7 29770
86. Dallolio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. Bianchi F, Nicassio F, Marzi M, Belloni E, EMBO Mol Med 2011 3 495 503
87. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, et al. J Clin Oncol 2010 28 1721 1726
88. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W, PLoS One 2011 6 17745
89. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY, J Gastroenterol Hepatol 2010 25 1674 1680
90. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW, Prostate 2011 71 326 331
91. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Kroh EM, Parkin RK, Mitchell PS, Tewari M, Methods 2010 50 298 301
92. Circulating miRNA signatures: promising prognostic tools for cancer. Heneghan HM, Miller N, Kerin MJ, J Clin Oncol 2010 28 573 574 author reply e575-576
93. Analysis of circulating microRNA: preanalytical and analytical challenges. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A, Clin Chem 2011 57 833 840
94. Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Luo SS, Ishibashi O, Ishikawa G, Ishikawa T, Katayama A, Mishima T, Takizawa T, Shigihara T, Goto T, Izumi A, et al. Biol Reprod 2009 81 717 729
95. Circulating MicroRNAs are Promising Novel Biomarkers of Acute Myocardial Infarction. Wang R, Li N, Zhang Y, Ran Y, Pu J, Intern Med 2011 50 1789 1795
96. Detection of microRNA expression in human peripheral blood microvesicles. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, et al. PLoS One 2008 3 3694
97. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S, PLoS One 2010 5 13735
98. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H, Breast Cancer Res 2010 12 90
99. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, Kong X, Int J Cancer 2011 10.1002/ijc.26422
100. Circulating microRNAs in breast cancer and healthy subjects. Zhu W, Qin W, Atasoy U, Sauter ER, BMC Res Notes 2009 2 89
101. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC, Transl Oncol 2010 3 109 113